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Breast cancer and combined oral contraceptives: results from a
multinational study
The WHO Collaborative Study of Neoplasia and Steroid Contraceptives*
Summary A collaborative, hospital-based case-control study was conducted at 12 participating centres in 10
countries. Based on data from personal interviews of 2,116 women with newly diagnosed breast cancer and
12,077 controls, the relative risk of breast cancer in women who ever used oral contraceptives was estimated to
be 1.15 (1.02, 1.29). Estimated values of this relative risk based on data from three developed and seven
developing countries were 1.07 (0.91, 1.26) and 1.24 (1.05, 1.47) respectively; these estimates are not
significantly different (P = 0.22). Estimates for women under and over age 35 were 1.26 (0.95, 1.66) and 1.12
(0.98, 1.27), respectively, and these estimates are also not significantly different (P = 0.38). Risk was highest in
recent and current users and declined with time since last use regardless of duration of use. Risk did not
increase with duration of use after stratifying on time since last use. Risk did not increase significantly with
increasing duration of use before age 25 or before a first live birth. However, a relative risk of 1.5 that was of
borderline statistical significance was observed in women who used oral contraceptives for more than 2 years
before age 25. No single source of bias or confounding was identified that could explain the small increases in
risk that were observed. Chance alone is also an unlikely explanation. The results could be due to a
combination of chance and potential sources of bias, or they could represent a weak causal relationship.
The results of studies of oral contraceptives and breast
cancer have recently been reviewed and quantitatively sum-
marised (Prentice & Thomas, 1987; Thomas, 1988). Sixteen
case-control and four cohort studies all found no significant
increase in risk of breast cancer in women who have ever
taken oral contraceptives. Of six case-control studies that
assessed risk in users of more than 10 years' duration, four
found no increase in risk in such users, and although one
found a significantly increased risk, another found a signi-
ficant reduction in risk. Risk of breast cancer was not found
to be altered from 10 to more than 20 years after initial use
of oral contraceptives in eight case-control and two cohort
studies.
Despite these consistent and reassuring findings, there
remain legitimate concerns that oral contraceptives may
enhance risk of breast cancer under some circumstances of
use. Findings from 14 studies that have assessed risk of
breast cancer in women who used oral contraceptives before
their first live birth or full-term pregnancy are inconsistent,
with eight showing no significant elevation in risk associated
with such use (Vessey et al., 1982; Hennekens et al., 1984;
Stadel et al., 1985; Lipnick et al., 1986; Meirik et al., 1986;
Paul et al., 1986; Miller et al., 1986; Jick et al., 1989), four
finding a significant trend of increasing risk with months of
use before the woman's first birth (Paffenbarger et al., 1980;
Pike et al., 1981; Harris et al., 1982; McPherson et al., 1987)
and two (Miller et al., 1989; UK National Case-Control
Study Group, 1989) finding an increased risk in young
women who used oral contraceptives both before and after
their first term pregnancy. Three case-control studies have
also found an increase in risk in women who first used oral
contraceptives before age 25 (Pike et al., 1983; Olsson et al.,
1985; Meirik et al., 1986), although four others have not
(Paul et al., 1986; Cancer and Steroid Hormone Study
(CASH), 1986; Miller et al., 1986, 1989). Since the reasons for
these discrepant findings are unknown, the influence of oral
contraceptives when used early in a woman's reproductive life
on subsequent risk of breast cancer requires further evaluation.
Another unresolved concern is whether women who are at
increased risk of breast cancer should take oral contra-
ceptives. Studies have not shown oral contraceptives to be
associated with an increase in risk of breast cancer in women
who are nulliparous, had their first child late in reproductive
life, or had a family history of breast cancer (Thomas, 1988).
Most studies have also not found an increase in risk in
relation to oral contraceptive use in women with a prior
history of benign breast disease (Kelsey et al., 1978; Brinton
et al., 1982; Vessey et al., 1983; Rosenberg et al., 1984;
CASH, 1986), including the two that specifically assessed risk
in women who used oral contraceptives after a benign breast
lesion developed (Brinton et al., 1982; CASH, 1986). Lees et
al. (1978), however, did find an increasing risk with duration
of use in women with prior benign lesions and Paffenbarger
et al. (1980) reported a similar result, but with a less striking
trend, in premenopausal women only; Miller et al. (1989)
also found an increase in risk in users with prior cystic
disease. Pike et al. (1981) reported risk in relation to use
before a woman's first term pregnancy to be particularly
enhanced in women with a history of benign breast disease.
These findings require confirmation. Also, the possible influ-
ence of oral contraceptives on risk of breast cancer in women
with and without other risk factors for breast cancer should
be evaluated.
Finally, almost all prior studies of breast cancer have been
conducted in economically developed countries with rela-
tively high incidence rates of this disease, and it is not certain
that results from such studies are applicable to less developed
countries where rates of breast cancer tend to be lower, and
where the primary determinants of risk and patterns of use of
oral contraceptives may be different from those in more
developed countries. The WHO Collaborative Study of Neo-
plasia and Steroid Contraceptives was conducted, in part, to
determine whether findings from studies of oral contracep-
tives and cancer in developed countries are similar to those
from less developed parts of the world. This paper is a report
of results from countries with varying levels of economic
development that addresses these outstanding issues regard-
ing combined oral contraceptives and breast cancer.
Methods
The methods used in this study have been previously des-
cribed (WHO Collaborative Study of Neoplasia and Steroid
Contraceptives, 1985). Data were collected in 12 participating
centres in Australia, Chile, the People's Republic of China,
Colombia, the German Democratic Republic (GDR), Israel,
Kenya, Mexico, the Phillippines and Thailand. Data were
collected from three separate centres in Thailand (Siriraj and
Chulalongkorn in Bangkok, and Chiang Mai). Some centres
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were individual hospitals; in others, data were collected from
more than one hospital. Data collection began between
October 1979 and November 1982, depending on the centre,
and ceased in September 1984, except in the GDR, China,
Thailand, Kenya and Mexico, where data collection con-
tinued past the time the analyses for this report began. This
report is based on data from cases and controls with com-
plete information at the co-ordinating centre as of 14 Feb-
ruary 1986.
In each hospital, cases were detected by monitoring all new
admissions to wards where women with breast cancer were
treated, and by checking outpatient gynaecological and
tumour clinics, and records of hospital pathology labora-
tories. Cases included all women diagnosed locally as having
a malignant breast tumour, born either after 1924 or after
1929 (depending on when oral contraceptives were first
locally available), and who resided during the preceding year
in a defined geographical area served by the hospital.
Controls were selected from among women admitted to
other than obstetric and gynaecological wards, who met the
same age and residential criteria for eligibility as the cases,
and who were not admitted for treatment of conditions
considered a priori possibly to alter contraceptive practices
(i.e. circulatory and cardiovascular diseases, diabetes, chronic
renal disease, benign breast disease, a previously diagnosed
malignancy, chronic liver disease, and any obstetrical or
gynaecological condition).
Approximately two controls were selected for each case,
but controls were not matched to individual cases. A list of
wards from which controls were to be selected was developed
for each hospital. Each week, wards were visited in the order
listed. At the time of a visit, all women eligible as controls
who were admitted to the ward within the past 24 hours were
selected as controls. The next ward on the list was then
visited, and this procedure was repeated until sufficient cont-
rols were selected to give a cumulative ratio of two controls
per case from the hospital. The same procedure was followed
in the next week, beginning with the ward listed after the last
one visited. This method resulted in a disproportionate
number of young controls, and after the first year of the
study it was modified so that during a fixed number of weeks
in each month (the number varying depending on the hos-
pital), only women in the older eligible age groups were
selected. As this was a study of cancers in addition to those
of the breast (i.e. cervix and corpus uteri, ovary and liver),
more than two controls per breast cancer case were available
for analysis.
A standardised questionnaire was administered to all study
subjects by specially trained female interviewers to obtain
information on the known and suspected risk factors for the
neoplasms under study, and a complete obstetric and cont-
raceptive history. Nearly all interviews were conducted in
hospitals. A calendar and samples of locally available oral
contraceptives were used to facilitate recall of times of use
and products taken. In addition, the medical records of
women who gave a history of oral contraceptive use were
reviewed when available, and in such instances information
from both interviews and these records were utilised by the
interviewers to record details of the women's use. The ques-
tionnaire was printed in the local language in all countries
except Kenya, where multiple languages are spoken, and the
Philippines, where English is widely used. Where the inform-
ation was not recorded directly on the English version ques-
tionnaire, it was transcribed on to an English version for
mailing to the co-ordinating centre in Seattle.
Pathologists at each centre were responsible for pro-
visionally diagnosing the cases, providing information on the
extent of disease at diagnosis and gross pathology, and
preparing stained histological slides for review. Slides from
all cases were sent to a single reference pathologist for
confirmation of diagnosis and uniform histological
classification according to the WHO histological classification
of breast tumours (World Health Organization, 1981).
The questionnaires, and forms from the local and reference
pathologists, were key entered and edited at the co-
ordinating centre. Errors that could not be corrected were
sent to the participating centres for clarification.
Only cases considered by the reference pathologist to have
invasive carcinoma of the breast are included. Table I shows
the proportions of eligible cases and controls that were
included in the analyses, and the reasons for all exclusions.
The proportion of cases not interviewed was less than 10%
in all centres except one, and ranged from 17.9 to 0%; the
proportion of controls not interviewed was less than 10% in
all but two centres, and also ranged from 17.9 to 0%. An
oral contraceptive history was obtained for nearly all cases
and controls. As described subsequently, variables that
appeared to confound the relationship between breast cancer
and oral contraceptive were controlled for, and the few cases
and controls with missing values for these variables were also
excluded from the analyses. Of the 2,116 cases, 75.4%,
10.9% and 5.2% had carcinomas classified as ductal, lobular
and apocrine, respectively; the remaining 8.5% had one of 15
other histological types.
Unless otherwise stated, unconditional logistic regression
analyses (Breslow & Day, 1980, p. 192) were utilised to
estimate relative risks, adjusted for various potentially con-
founding variables; and all variables were entered into the
regression models as categorical variables. To control for
multiple factors simultaneously, a final model containing
confounding variables was constructed. Variables were
entered into models sequentially, one at a time, and retained
if the associated X2 test for goodness of fit was significant
(P<0.05) and if the resultant relative risk in relation to ever
use of oral contraceptives was appreciably altered. This
model was then used to estimate relative risks and their 95%
confidence interval under various conditions of use. Since
cases tended to be older than controls, and since both the
ratio of controls to cases and the prevalance of use of oral
contraceptives varied among the centres, all relative risk
estimates were controlled for age and centre.
Table I Numbers ofeligible cases and controls accrued and numbers
excluded from analyses by reason for exclusion
Cases Controls
Subjects No. % No. %
Total accrued 2,288 100.0 14,113 100.0
Not interviewed 132 5.8 767 5.4
Oral contraceptive use unknown 4 0.2 12 0.1
Missing values for > 1 confounders 36 1.6 262 1.9
Included in analysis 2,116 92.5 13,072 92.6
Results
Estimates ofrelative risk in women who ever used oral
contraceptives
Table II shows relative risks of breast cancer, adjusted for
age and centre, in relation to various previously recognised
risk factors for this disease. As expected, risk of breast cancer
is increased in women with a prior history of a biopsy for
benign breast disease. Risk also increases with the age at
which a woman first gave birth to a live child. Women who
have never been pregnant and women who have previously
been pregnant but have not delivered a living child are also
at increased risk relative to women with a first birth at a
young age. The relative risk of breast cancer decreases with
increasing number of live births. Single women are at greater
risk than women who have ever been married. Women whose
mother or grandmother (maternal or paternal) had breast
cancer are also at increased risk. Risk is reduced in women
with an early menopause. Age at menarche does not appear
to be an important determinant of risk. Risk is seen to
increase with the number of years that a woman has spent in
school. Most women in this study were also classified into
one of two occupational classes to reflect socio-economic
status, and women in the high occupational class were at
somewhat greater risk than women in the lower class (not112 WHO COLLABORATIVE STUDY
Table II Relative risks of breast cancer in relation to various
previously recognised risk factors
Level No. ofsubjects Relative riska
Variable ofvariable Cases Controls (95% CI)
Benign breast lesion No 1942 12,666 1.00
Yes 174 406 1.84 (1.51, 2.24)
Age at first live <20 322 3,324 1.00
birth 20-24 817 4,544 1.55(1.35, 1.79)
25-29 442 1,734 2.12 (1.80, 2.49)
>30 210 663 2.71 (2.21, 3.32)
No live birth 54 245 2.31 (1.64, 3.25)
Never pregnant 270 2,556 2.23 (1.85, 2.69)
Unknown 1 6 -
No. of live births None 324 2,801 1.09 (0.94, 1.27)
1-2 825 3,809 1.00
3-4 686 3,366 0.80 (0.71, 0.90)
5-8 244 2,513 0.44 (0.38, 0.52)
>9 37 583 0.29 (0.20, 0.41)
Marital status Single 198 2,249 1.00
Married 1,655 9,100 0.80 (0.67, 0.95)
Sep./div. 167 1,090 0.79 (0.62, 1.00)
Widow 96 633 0.75 (0.57, 0.99)
Family history of No 2,003 12,913 1.00
breast cancer Yes 113 159 3.11 (2.38, 4.06)
Age at menopauseb Pre-menop. 1,726 10,591 1.00
>50 62 288 0.91 (0.66, 1.26)
45-49 169 1,020 0.63 (0.52, 0.77)
<44 159 1,168 0.58 (0.48,0.70)
Unknown 0 5
Age at menarche S 11 160 836 1.00
12-13 882 4,113 1.28(1.05, 155)
14-15 728 4,985 1.10(0.90, 1.34)
>16 341 3,084 0.98 (0.78, 1.23)
Unknown 5 54
Years of schooling 0 157 1,405 1.00
1-6 558 5,484 1.18 (0.97, 1.44)
7-12 932 4,540 1.66 (1.35, 2.03)
>13 469 1,643 2.49(2.00,3.11)
Socio-economic IV (low) 90 790 1.00
index III 542 4,969 1.11 (0.87, 1.42)
II 609 4,068 1.33 (1.04, 1.70)
I (high) 875 3,245 2.07 (1.61, 2.65)
aAdjusted for age and centre. bIncludes both natural and artificial
menopause.
shown). A four category socio-economic status index was
derived from years of education and occupation (or occupa-
tion of husband if the woman was a housewife). Women of
high social class according to this index were at approx-
imately twice the risk of breast cancer compared to women in
the lower social class. All of the variables in Table II, and
others described below, were considered as possible con-
founders in the analysis of oral contraceptives in relation to
risk of breast cancer.
Of the 2,116 cases, 579 (27.4%) had ever used combined
oral contraceptives, and an additional 141 (6.7%) had used
only oral contraceptives of an unknown type. Among the
13,072 controls, 3,671 (28.1%) had ever used combined oral
contraceptives, and 756 (5.8%) others had only used un-
known types. Of the women who had used combined prod-
ucts, 6.6% of the case users and 3.4% of the control users
had also used sequential or continuous preparations; and
5.3% of the case users and 4.7% of the control users had
also used oral contraceptives of unknown type. Only 3.3% of
the total cases and 1.7% of the total controls had used only
sequential products, and just 1.0% of the cases and 0.6% of
the controls had used only continous types.
The relative risk of breast cancer in women who ever used
combined oral contraceptives was estimated to be 1.15 (1.02,
1.30) after controlling for age and centre. Since most cont-
raceptives of known type were combined preparations, it can
safely be assumed that most of the unknown types were
actually combined products. Also, the age and centre
adjusted relative risk of breast cancer in women who ever
used unknown type oral contraceptives was estimated to be
1.12 (0.93, 1.35), which is very similar to the value for
combined products. Therefore, use of either combined or
unknown types of oral contraceptives was assumed to repre-
sent exposure to combined oral contraceptives. Using this
definition of exposure, the relative risk was again found to be
1.15, after controlling for age and centre. This definition of
exposure to combined oral contraceptives was used in all
subsequent analyses presented in this report.
The age adjusted estimates of the relative risks were not
found to differ significantly among centres. Data from all
centres were therefore combined in analyses to identify and
control for confounding variables. When age, centre and the
variables age at first live birth and nulliparity (as a single
variable), socio-economic index, calendar year of marriage
and use of an IUD were added into regression models, each
was found to have confounding effects on the relative risk
after controlling for the other variables in the model. These
effects, however, were not in a uniform direction, and the
final estimate of the relative risk based on this model was
identical to that obtained when controlling only for age and
centre. It is shown at the bottom of Table III.
Calendar year of marriage was considered a confounder
because availability of oral contraceptives has changed over
time, and there have been temporal changes in incidence
rates of breast cancer in some countries. Use of an IUD was
not suspected a priori to be a confounding variable, and
controlling for all of the variables in the final model except
use of an IUD resulted in an estimate of the relative risk of
1.12 (1.00, 1.26). Unless otherwise stated, the results present-
ed subsequently are based on analyses in which use of an
IUD was included as a confounding variable, but in all
instances, results were similar to those obtained when
estimates of relative risks were not controlled for IUD use.
A large number of other variables related to menstruation,
child bearing, socio-economic status, access to medical ser-
Table III Relative risks ofbreast cancer in women who ever used combined or unknown type oral
contraceptives
Cases Controls Relative risk'
Centre Users Non-users Users Non-users (95% CI)
Australia 37 27 436 241 0.94 (0.55, 1.60)
Chile 28 93 211 682 1.03 (0.64, 1.65)
China 18 87 55 382 1.28 (0.71, 2.32)
Colombia 6 21 68 148 1.11 (0.42, 2.93)
GDR 169 105 411 259 1.17(0.87, 1.57)
Israel 232 585 649 1389 1.05 (0.87, 1.27)
Kenya 9 21 183 470 1.11 (0.50,2.50)
Mexico 26 59 315 748 1.24 (0.76, 2.02)
Philippines 43 157 243 945 1.30 (0.89, 1.90)
Chiang Mai 59 65 619 1018 1.70 (1.16, 2.48)
Chulalongkorn 40 69 608 871 0.87 (0.58, 1.31)
Siriraj 53 107 629 1492 1.30 (0.91, 1.84)
Total 720c 1396 4427d 8645 1.15 (1.02, 1.29)b
aControlled for age, age at first live birth, socio-economic index, year ofmarriage, and use ofan
IUD. bControlled also for centre. clncluding 141 users of unknown type. dIncluding 756 users of
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vices and exposure to exogenous hormones were also con-
sidered as possible confounders, and none had an additional
influence on the relative risk in users of oral contraceptives.
These additional variables include: numbers of pregnancies
and live births; ages at first breast feeding and last preg-
nancy; months of lactation; marital status; outcome of first
pregnancy; years of schooling; occupation; ethnic origin
(Israel only); husband's years of schooling; husband's
occupation; method of payment for medical care; calendar
years of birth and menarche; ages at menarche and
menopause; history of benign breast disease; family history
of breast cancer; history of infertility; source of referral to
hospital; calendar year of interview; use of reserpine;
numbers of chest X-rays and prior pap smears; several
indices of use of hormones for non-contraceptive purposes;
use of sequential, continuous, post-coital or injectable steroid
contraceptives; duration of residence at current address; and
consumption of alcoholic beverages.
Since the value of 1.15 for the relative risk, although not
large, was of borderline statistical significance, and hence
somewhat at variance with results from most other studies,
possible reasons for this finding were investigated. An
interaction term for centre and use of oral contraceptives was
included in the final model to provide separate estimates of
the relative risk for each individual centre. These are shown
in Table III. Although these estimates did not vary
significantly, that for Chiang Mai was larger than those for
the other centres and was the only one with a lower 95%
confidence limit great than 1. The data from Chiang Mai
were therefore further evaluated for evidence of possible bias.
The observed increase in relative risk could not be attributed
to confounding by any additional variables not included in
the analyses shown in Table III, variation in data collected
by different interviewers, or under-representation of oral con-
traceptive use in controls in any particular diagnostic
category.
The determinants of oral contraceptive use may vary
among countries and cultures. The variables identified as
confounders from analyses of data from all centres combined
may therefore not be the most important confounders in
some individual centres. Separate analyses of the data from
each centre were therefore performed, using the same step-
wise regression technique that was utilised to analyse the
data from all centres combined. The values for the resultant
relative risks did not vary appreciably from those in Table
III. A x2 test for heterogeneity among the individual esti-
mates for each centre was not significant. Based on an
average of the individual estimates for each centre, weighted
by the inverse of their variance (Prentice & Thomas, 1987), a
summary relative risk of 1.13 (1.00, 1.28) was obtained. Since
this estimate is very close to that of 1.15 obtained from the
combined analysis of data from all centres, and for ease in
computation, the model developed for all centres combined
was used for most subsequent analyses.
Duration, latency and recency of use
Table IV shows estimates of the relative risk of breast cancer
in relation to years of use (duration), time since first use
(latency) and time since most recent exposure (recency). A
statistically significant trend of increasing risk with years of
use was observed. Among users, risk declined with years
since first use, but the trend was not significant. The relative
risk is highest in current users, and among users a steady and
significant decline in risk with time since last exposure is
evident.
If a woman gave a history of having used oral contracep-
tives, an attempt was made to obtain additional or
confirmatory information from her medical records on brand
names and periods of use. This procedure would not alter the
classification of a woman as having ever used oral contracep-
tives, because medical records of women without a history of
use were not reviewed, and if use by a woman who claimed
to have taken oral contraceptives could not be confirmed
from medical records, she was still considered to be a user.
Table IV Relative risks ofbreast cancer in relation to duration ofuse,
time since first use, and time since last use of combined oral contra-
ceptivesa
Relative riskb
Category ofuse Cases Controls (95% CI)
Non-users 1395 8640 1.00
Years of usec
<1 247 1670 1.12(0.95, 1.31)
1-2 194 1397 1.01 (0.82, 1.23)
3-8 126 735 1.17(0.97, 1.42)
>8 123 417 1.56 (1.23, 1.98)
P value for trend test 0.007
Years since first used
<3 44 494 1.39 (0.98, 1.96)
3-9 194 1293 1.30(1.08, 1.57)
10-15 300 1569 1.14(0.97, 1.33)
>15 162 930 1.00(0.82, 1.21)
P value for trend testg 0.12
Months since last usee
Current users' 127 747 1.66 (1.32, 2.08)
4-35 120 751 1.41 (1.13, 1.77)
36-108 234 1374 1.16(0.98, 1.37)
> 109 213 1388 0.91 (0.77, 1.08)
P value for trend testg 0.0001
aUsers of unknown type oral contraceptives assumed to have used
combined type. bAdjusted for age, centre, age at first live birth,
socio-economic index, year ofmarriage, and use ofan IUD. One case
and six controls with unknown age at first live birth excluded.
cExcluding 30 cases and 207 controls with unknown years of use.
dExcluding 20casesand 140controlswith unknownyearssincefirst use.
eExcluding 26 casesand 166 controls with unknown years since last use.
'Including women who discontinued use in the past three months.
gTrend test based on data from exposed subjects.
These procedures would also have had a minimal effect on
classifying a woman as ever having used combined oral
contraceptives (including unknown types), since few other
types of oral contraceptives were available, and few women
erroneously reporting use of combined preparations would
have been reclassified as having used a non-combined prod-
uct, or vice versa. Therefore, the estimated values of the
relative risk of breast cancer in women who ever used com-
bined oral contraceptives could not have been appreciably
influenced by any differences in the proportion of cases or
controls whose oral contraceptive histories were supp-
lemented by information from medical records. Such
differences could, however, alter estimated values of the
relative risk in relation to such features of use as duration,
latency or recency. Information from medical records was
obtained for 27% of the case users and 18% of the control
users. These percentages varied widely among participating
centres, from 0 to 94% of the cases and 0 to 89% of the
controls. Information was most frequently obtained from the
medical records of long-term and current or recent users in
both the case and control groups. However, results similar to
those in Table IV were obtained separately from countries in
which information from medical records was obtained for
relatively high and low proportions of users, and in individ-
uals whose use was ascertained solely from interviews and
from both interviews and medical records. Any differences
between cases and controls in the fidelity of the efforts to
obtain information on use of oral contraceptives from
medical records is thus not a likely explanation for any
increased risks that are observed.
Table V shows that the possible increase in risk in long-
term users of oral contraceptives is evident in all categories
of latency (years since first use). However, Table VI shows
that this possible increased risk in long-term users is due to
an association between years of use and months since last use
(recency). No increase in risk with duration of use is seen in
any category of recency, but risk declines with time since last
use for all categories of duration.
Use in women with riskfactorsfor breast cancer
Exploratory analyses using the model developed for all
women combined resulted in relative risk estimates in rela-114 WHO COLLABORATIVE STUDY
Table V Relative risksa ofbreast cancer in relation to duration ofuse
and years since first use of combined oral contraceptivesb
Years ofuse
Years sincefirst use <1 1-2 3-8 >8
<3 1.41 1.35 - -
3-9 1.28 1.36 1.22 2.48
10-15 0.97 0.93 1.33 1.68
>15 1.05 0.90 0.68 1.35
aRisks are relative to risk in non-users, adjusted forage, centre, ageat
first live birth, socio-economic index, year of marriage and use of an
IUD. bUsers ofunknown type oral contraceptives are assumed to have
used combined type.
Table VI Relative risksa ofbreast cancer in relation to duration ofuse
and years since last exposure to combined oral contraceptivesb
Years ofuse
Months since last use <1 1-2 3-8 >8
Current usersc 2.07 1.41 1.19 2.16
4-36 1.23 1.63 1.53 1.38
37-108 1.23 1.10 1.20 1.12
109 1.01 0.88 0.60 0.76
aRisks are relative to risk in non-users, adjusted for age, centre, age at
first live birth, socio-economic index, year of marriage and use of an
IUD. bUsers ofunknown type oral contraceptives are assumed to have
used combined type. cIncludes women who discontinued use in the past
3 months.
tion to use of oral contraceptives that were higher in women
under than over age 35. Some risk factors for breast cancer
may have effects in young women opposite to those in older
women (Janerich & Hoff, 1982); and in this study the
variables most strongly associated with breast cancer were
different for women under and over age 35 (not shown). A
separate model was therefore developed to estimate relative
risks of breast cancer in relation to combined oral contra-
ceptives in women under age 35. This was developed in the
same manner as the model for women of all ages considered.
The final model for women less than 35 contained the follow-
ing variables: age, centre, husband's occupation, years of
schooling, number of live births, age at first live birth, year
of birth and family history of breast cancer. As shown in the
upper portion of Table VII, the estimated relative risk of
breast cancer in women under age 35 who ever used oral
contraceptives is 1.26. The estimated relative risk for older
women, using the original model to analyse data separately
from such women, was 1.12. These two values do not differ
significantly (P value of X2 test for heterogeneity = 0.38).
The mean of these two estimates weighted by the inverse of
their variance provides an overall estimate of 1.14 (1.02,
1.27). Because this estimate is similar to the overall estimated
relative risk of 1.15, the original model was used in analyses
that included women of all ages. Analyses of data on women
under age 35 were based on the model developed for that age
group.
A relative risk of greater than I in women under age 35
was observed in seven of the 10 centres from which sufficient
data were available to provide an estimate of the relative risk
in such women, and a X2 test for heterogeneity showed the
variation in the estimates for the various centres to be
explainable on the basis of chance (P = 0.36). The relative
risks in relation to years of use, time since first use and time
since last use were not consistently greater in women less
than 35 than in older women, and the trend of increasing risk
with duration of use shown in Table IV for women of all
ages was no stronger in the younger than older groups of
women.
As shown in Table VII, no statistically significant interac-
tions were observed between use of oral contraceptives and
age at first live birth and nulliparity, outcome of first preg-
nancy, socio-economic index or family history of breast
cancer.
The effect on risk of breast cancer of use of oral contracep-
tives before and after a biopsy for a benign breast lesion was
assessed from data on the 174 cases and 406 controls who
gave a history of such a lesion. Use before their benign lesion
was reported by 31 cases and 77 controls; and use afterwards
was reported by 26 cases and 68 controls. The relative risk of
breast cancer was not significantly enhanced either in women
who used oral contraceptives before their prior breast biopsy
(RR = 1.30; 95% CI = 0.75, 2.27) or after (RR = 0.97; 95%
CI = 0.54, 1.72). These estimates were calculated controlling
for the same variables as in Table III.
Table VII Relative risks of breast cancer in relation to use of combined oral
contraceptivesa in women characterised by various risk factors for breast cancer
P value ofX2
Cases Controls Relative riskb testfor
Variable User Non-user User Non-user (95% CI) heterogeneity
Age
<35 160 141 1613 2722 1.26 (0.95,1.66) 0.38
>35 560 1255 2814 5923 1.12(0.98,1.27)
Age at first live birthc
<24 424 715 3068 4800 1.17(1.02,1.36) 0.36
25-29 171 271 670 1064 1.27(1.01, 1.61)
>29 69 141 234 429 1.13 (0.79,1.60)
No live birth 19 35 108 137 0.75 (0.38, 1.47)
Never pregnant 37 233 346 2210 0.84(0.56, 1.25)
Outcome of first pregnancy
Viable 577 979 3553 5718 1.22 (1.08, 1.39) 0.34
Non-viable 87 149 420 580 0.96 (0.70, 1.32)
Nulliparous 56 268 454 2347 0.80 (0.56, 1.13)
Socio-economic index
IV (low) 19 71 156 634 1.86 (1.07, 3.24) 0.33
III 142 400 1498 3471 1.13 (0.91, 1.40)
II 202 407 1420 2648 1.14 (0.94, 1.39)
I (high) 357 518 1353 1892 1.12 (0.94,1.32)
Family history of breast cancer
No 669 1334 4349 8564 1.13 (1.01, 1.27) 0.65
Yes 51 62 78 81 1.27 (0.75, 2.16)
'Users ofunknown type oralcontraceptives are assumed to have used combined types.
bRisks are relative to risk in non-users. All are adjusted for age, centre, age at first live
birth, socio-economic index, use ofan IUD and year ofmarriage, except for the relative
risk in women less than 35 years old, which is adjusted for age, centre, husband's
occupation, years ofschooling, number oflive births, age at first live birth, year ofbirth
and family history ofbreast cancer. cExcluding one case and six controls with unknown
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Use in developed and developing countries
Since one purpose of this study was to determine whether
results of studies of oral contraceptives and breast cancer
conducted in developed countries are similar to results from
developing countries, it was decided a priori to estimate
relative risks separately for women in developed and develop-
ing nations. For this purpose data from the three most
economically developed countries in this study were com-
bined, as were data from the remaining seven less developed
countries. The three countries that were considered developed
for this purpose were Australia and Israel, which have high
rates of breast cancer, and the German Democratic Republic,
which has moderately high rates (Muir et al., 1987). The
seven other countries are either known to have lower
incidence rates of breast cancer, or can reasonably be
assumed to have low rates because of their adjacency and
economic similarity to known low incidence nations (Water-
house et al., 1982; Muir et al., 1987).
As shown in Table VIII, the relative risk in women who
ever used oral contraceptives is somewhat greater for women
in developing than developed countries, although the
observed difference could have occurred by chance
(P = 0.22). The values of the relative risks in most categories
of duration, latency and recency are also higher in the
developing countries, although the differences are small, and
also not statistically significant. The trends of increasing risk
with duration of use and times since first and last exposure
are also somewhat stronger in the developing countries.
No trends of increasing or decreasing relative risk in oral
contraceptive users with age were observed in either group of
countries. Relative risks in all women under age 35 were
similar in developing and developed countries, although a
relative risk of 3.05 (1.69, 5.51) was found in the youngest
group of women (less than 29) in developing countries (based
on 23 exposed cases and 644 exposed controls).
Use in early reproductive life
The observed effect of oral contraceptives on risk of breast
cancer did not vary significantly among women who first
used these products at various ages. The highest relative risk
(1.42; 95% CI = 1.04, 1.58) was observed in women who first
began using them after the age of 35.
Relative risks of breast cancer in relation to duration of
use of oral contraceptives before age 25 are shown in the
upper portion of Table IX. A steady trend of increasing risk
with years of use is not evident (P value of test for trend =
0.31), but the relative risks for users of more than 2 years'
duration are increased and of borderline statistical signi-
ficance. Most exposure to oral contraceptives before age 25
occurred in women under age 35. In such women, risk also
did not steadily increase with months of use before age 25,
although the relative risk for women with more than 3 years
of use was 1.63 (0.95, 2.80), based on 26 exposed cases and
189 exposed controls. Results regarding use before age 25
were similar in developed and developing countries.
As shown in the lower portion of Table IX, no trend of
increasing risk with duration of use of oral contraceptives
before a woman's first live birth was observed, although a
small relative risk of 1.24, with confidence limits that include
1.0, was found in women with such use for over 2 years.
Because use before a woman's first birth has been associated
with an increased risk of breast cancer in several studies, the
small elevation in relative risk estimated in this investigation
was evaluated further. The possible increase in risk was
found to be confined to women who had had a non-viable
pregnacy before their first live birth. In these women, risk
increased with duration of use before their first live birth,
and in women with such use for over 2 years, a relative risk
of 2.56 (1.05, 6.23) was estimated, based on 10 exposed cases
and 29 exposed controls. There were too few women with
sufficient use before their first live birth to determine whether
risk is enhanced in long-term users after a prolonged time
since initial exposure. Only 2 cases and 11 controls had
initially been exposed to oral contraceptives over 10 years
previously, and had used them for more than 5 years before
their first live birth.
Tumour size and stage
It has been suggested (Skegg, 1988) that women who use oral
contraceptives may be more likely to have their breast cancer
detected at an early stage than non-users. If so, then this
would result in an observed excess relative risk of small, early
stage tumours, and this might be particularly evident in
younger age women if there was a shortening of time from
onset of disease to detection. If this source of bias were
Table VIII Relative risks of breast cancer in developed and developing countries in
relation to various measures of use of combined oral contraceptives
Developed countriesa Developing countries'
No. ofsubjects Relative riskc No. ofsubjects Relative riske
Category ofuse Cases Controls (95% CI) Cases Controls (95% CI)
Non-user 716 1888 1.00 679 6752 1.00
Any use 438 1496 1.07 (0.91, 1.26) 282 2930 1.24(1.05, 1.47)
Years of used
<1 134 418 1.07(0.85,1.35) 113 1252 1.17(0.93,1.46)
1-3 101 439 0.88 (0.68,1.13) 93 958 1.30 (1.01, 1.66)
4-8 88 307 1.11 (0.84, 1.47) 38 428 1.09(0.76, 1.56)
>8 89 206 1.39 (1.03,1.88) 34 211 1.88 (1.27, 2.78)
P value for trend test 0.13 0.01
Years since first usee
<3 18 101 1.25 (0.71, 2.19) 26 393 1.46 (0.94, 2.27)
3-9 105 400 1.08 (0.83, 1.40) 89 893 1.56 (1.21, 2.03)
10-15 200 560 1.17(0.95, 1.45) 100 1009 1.12(0.88, 1.43)
>15 96 350 0.89(0.68, 1.16) 66 580 1.13(0.85,1.50)
P value for trend testg 0.44 0.10
Months since last use'
<3 and current 78 1888 1.53 (1.12, 2.10) 49 492 1.86 (1.34, 2.60)
4-35 76 262 1.31 (0.96. 1.77) 44 489 1.55 (1.10, 2.18)
36-108 143 457 1.07(0.85, 1.35) 91 917 1.28(1.00, 1.64)
109 117 409 0.85 (0.67,1.07) 96 979 1.00 (0.79,1.28)
P value for trend test5 0.01 0.002
aIncludes Australia, German Democratic Republic and Israel.bIncludes Chile, Colombia,
China, Kenya, Mexico, Philippines and Thailand. cControlled for age, centre, age at first
live birth, socio-economic index, year ofmarriage and use ofan IUD. One case and six
controls with unknown age at first live birth excluded. dExcluding 30 cases and 207
controls with unknown duration of use. eExcluding 20 cases and 140 controls with
unknown time since first use. 'Excluding 26 cases and 166 controls with unknown time
since last use. gTrend test based only on data from exposed subjects.116 WHO COLLABORATIVE STUDY
Table IX Relative risks ofbreast cancer in relation to duration ofuse
of oral contraceptives before age 25 years and before first live birth
Months No. ofsubjects Relative risk'
Time ofuse of use Cases Controls (95% CI)
Before age 25 None 1,908 11,104 1.00
yearsc <12 82 881 1.02 (0.79, 1.32)
12-24 37 421 0.79 (0.55, 1.14)
25-36 29 207 1.51 (0.98, 2.31)
> 37 29 243 1.49 (0.97, 2.28)
Before first live None 1,691 9,660 1.00
birthd Any 87e 548C 0.91 (0.69, 1.20)b
<2 56f 405f 0.82 (0.59, 1.13)b
, 2 29 110 1.24 (0.78,1.97)b
'Controlled for age, centre, age at first live birth and nulliparity,
socio-economic index, year ofmarriageand use ofan IUD. bControlled
also for use of oral contraceptives after a first live birth. cExcludes 31
cases and 216 controls with unknown use before age 25. dExcludes 325
cases and 2,825 controls with no live birth. eExcludes 13 cases and 39
controls with unknown use before first life birth. fExcludes two
additional cases and 33 additional controls with unknown duration of
use before first live birth.
operating one would also expect to observe an increase in
relative risk primarily in relation to current and recent users,
and such users would also tend to have small, early stage
tumours.
Among all cases in this study, 43.3% of those who had
ever used oral contraceptives presented with small tumours
(<3 cm), compared to 38.3% of non-users. However, after
adjusting for confounding variables considered in previous
analyses, relative risks were not found to be enhanced pre-
dominantly for smaller tumours in all women who ever used
oral contraceptives, in users under age 35, or in users in
developing countries. Risk in users was also not preferentially
enhanced for tumours confined to the breast compared to
tumours with local spread or distant metastasis. Also, the
increases in risk in relation to long-term, current and recent
use of oral contraceptives were observed for tumours of all
sizes. It is therefore unlikely that selective detection of cases
in women who used oral contraceptives can explain the
observed overall increase in risk, or the possible increases in
young women, in developing countries, or in long-term,
recent and current users.
Tumours in women who used oral contraceptives for more
than 36 months before they were 25 years old tended to be
small (73.9% of 23 of known size were less than 3 cm in
diameter), although tumours in users of 25-36 months' dura-
tion, who had an equally high relative risk, did not (37.5% of
24 tumours were less than 3 cm). Thus, preferential screening
in young women who have been long-term users of oral
contraceptives may partly account for the findings in the
upper part of Table IX, but it is probably not the total
explanation. On the other hand, women with a prior non-
viable pregnancy before their first live birth, who used oral
contraceptives before their first live birth, more frequently
had small tumours (less than 3 cm in diameter) than similar
women who had not used oral contraceptives before their
first live birth (59.2% of 13 tumours of known size vs 33% of
15 tumours). Also, in users before their first live birth with a
prior non-viable pregnancy, age and centre adjusted relative
risks were 4.44 (1.35, 14.6), 1.33 (0.26, 6.95) and 0.74 (0.08,
7.05) for tumours that were <3, 3-4 and >4 cm in dia-
meter, based respectively on nine, three and one exposed
cases, and 47 exposed controls. The small increase in risk in
relation to use before a first live birth (Table IX) may
therefore be due to selective early diagnosis of breast cancer
in women with such use, if they had had a prior non-viable
pregnancy.
Composition oforal contraceptives
Details of results in relation to oral contraceptives ofvarying
compositions will be the subject of a separate report, and
only observations of value in interpreting the findings pre-
sented in this paper are summarised here. Relative risks of
breast cancer in relation to 22 different combined oral con-
traceptives were estimated from data on non-users and
women who had used a single (known) combined product.
Relative risks in women who ever used these products were
less than 1 for nine formulations, and greater than 1 for 13.
The relative risks ranged from 0.74 to 1.43 among 21 pill
types, and a relative risk of 8.19 (1.94, 34.6), based on four
exposed cases and five exposed controls, was observed for
one product (1 mg lynestrenol plus 0.1 mg mestranol). The
products associated with the higher relative risks tended to be
those used more frequently both in women under age 35 and
in developing countries. However, the products associated
with high relative risks did not differ consistently from those
associated with lower relative risks by type of oestrogen or
progestagen, or by the dosages of either of these constituents.
Also, it was possible to estimate relative risks in relation to
three specific formulations both for women under age 35 and
for older women; and the relative risks in users of all three
products were higher in the younger than in the older age
group. Similarly, the relative risks were higher in developing
than developed countries for both of the formulations for
which it was possible to make individual estimates of the
relative risk in each of the two groups of countries. It is
therefore unlikely that any differences in relative risks
associated with oral contraceptives in developed and develop-
ing risk countries and in younger and older women are due
to use of different oral contraceptives with different degrees
of carcinogenicity for the breast.
There were too few data for analysis to determine whether
the enhanced risks shown in Table IX are specific for partic-
ular types of oral contraceptives.
Discussion
Estimates of the relative risk of breast cancer in women who
ever used oral contraceptives were recently estimated to be
1.0 (0.9, 1.1) and 1.0 (0.8, 1.1) based on combined data from
16 previous case-control and four cohort studies, respectively
(Thomas, 1988). Nearly all of these prior studies were con-
ducted in developed countries with relatively high rates of
breast cancer. Although the relative risk of 1.15 (1.02, 1.29)
estimated in this study is not incompatible with these sum-
mary estimates, it is higher than that found in most prior
investigations. The estimates for women in developed and
developing countries in this study did not differ significantly,
but the value for developing countries was the higher of the
two, and contributed to most of the possible small overall
elevation in risk that was observed. The estimated relative
risk of 1.07 (0.81, 1.26) in women in the three developed
countries who ever used oral contraceptives is close to the
summary estimates of Thomas (1988). Also, the relative risk
of 0.9 in women in these three countries who were initially
exposed over 15 years previously is identical to the value
estimated from the eight prior case-control studies that pro-
vided relative risks for women initially exposed from over 10
to over 20 years in the past (Thomas, 1988). In contrast, the
point estimate of the relative risk for women in the develop-
ing countries was 1.24 (1.05, 1.47) in women who ever used
oral contraceptives and this is greater than values obtained
from all but four (Kelsey et al., 1978; Pike et al., 1981; Miller
et al., 1989; UK National Case-Control Study Group, 1989)
of 19 previous case-control studies, and from all but one
(Kay & Hannaford, 1988) of four previous cohort studies
(Thomas, 1988; Kay & Hannaford, 1988; Vessey et al., 1989)
conducted in developed countries. Results from the few
studies of oral contraceptives and breast cancer in developing
countries (Lee et al., 1987; Yuan et al., 1988) have yielded
inconsistent results. Since the results from this study, partic-
ularly those from developing countries, may be at variance
with results from most prior investigations, possible reasons
for a spurious increase in risk must be considered.
Because this study was conducted in part in countries with
limited medical care facilities, some cases may not come to
medical attention. If such cases were also those less likely toBREAST CANCER AND ORAL CONTRACEPTIVES 117
have received other medical services, including family plan-
ning services, then the (hospitalised) cases included in this
study would be more likely to have used oral contraceptives
than the hypothesised missed cases, and this could result in a
spurious increase in relative risk in relation to oral contra-
ceptive use. This possible source of bias was anticipated when
the study was planned, and resulted in the decision to select
hospital controls, rather than controls from the same village
or neighbourhood as the cases. This as least partly controlled
for (unknown) factors that determine entry into the medical
care system and admission to the hospitals in which the study
was conducted. Information was also obtained on various
indices of medical care utilisation, such as prior pap smears
and chest X-rays, and control for these factors did not alter
the estimated values of the relative risks in oral contraceptive
users.
Conversely, a bias in the opposite direction could have
resulted because some hospitals served both as referral cen-
tres for such serious and relatively unusual conditions as
breast cancer, and also as local, general hospitals; and if
access to contraceptive services is better in areas in proximity
to the hospital than in more distant regions, and if cases
came from a wider catchment area than the controls, then
this would lead to a spuriously low relative risk. To reduce
the possibility of this source of bias, cases and controls were
restricted to defined geographical areas served by the hos-
pitals. These areas were often quite large, however. To reduce
further the possibility of this source of bias, a detailed
residential history was ascertained for all study subjects, so
that estimates of relative risks could be controlled for place
of residence (urban centre, town, rural village) and mobility.
Controlling for such variables did not alter the results of this
study.
Another possible explanation for a spurious increase in
relative risk is that the hospital controls had diseases that
were associated with under-use of oral contraceptives. To
reduce this source of bias, individuals who were hospitalised
for conditions known or perceived to be related to use of
oral contraceptives, or contra-indications to their use, were
not eligible for selection as controls. Furthermore, the cont-
rols consisted of women with a large variety of medical
conditions, and use of oral contraceptives did not vary
greatly among women in the various diagnostic categories.
Under-utilisation of oral contraceptives in some diagnostic
groups of controls therefore cannot explain the observed
increase in relative risk.
Bias due to more intensive screening for breast cancer in
oral contraceptive users than in non-users also cannot ex-
plain the overall increase in relative risk observed, or the
increase in long-term users, or in recent and current users.
The relative risks in relation to these features of use did not
vary appreciably by tumour size or stage of disease at dia-
gnosis. Also, non-invasive carcinomas were not considered in
this report, in part because they would be the most likely
malignancies to be detected by screening.
Another possible reason for a spuriously enhanced relative
risk is more complete recall of prior use of oral contracep-
tives by cases than controls. Utilisation of hospitalised
women as controls reduced the possibility of this occurring.
Furthermore, if this had occurred, one would also expect to
observe an enhanced relative risk of other cancers in relation
to oral contraceptives. On the contrary, use of oral contra-
ceptives has been found in this study to be associated with a
reduced risk of cancer of the endometrium (WHO Collabo-
rative Study of Neoplasia and Steroid Contraceptives, 1988)
and ovary (WHO Collaborative Study of Neoplasia and
Steroid Contraceptives, 1989) and the estimates of the
relative risks of these neoplasms in users of oral contracep-
tives are similar in magnitude to those from prior studies
(Prentice & Thomas, 1987). Also, results from this study in
relation to such details of use as duration, recency and
latency were similar in individuals whose oral contraceptive
use was ascertained only from interviews and in those whose
information on use was supplemented by a review of medical
records.
Spurious results could also have resulted from confounding
by risk factors for breast cancer that are also related to use
of oral contraceptives. This is unlikely because most of the
known risk factors for breast cancer were considered, and
information on them was most probably correctly ascer-
tained, because these factors were found to be related to
breast cancer in this study (Table II). Possible risk factors
that were not considered are obesity and high fat diet.
Obesity is an unlikely confounder in this study because most
women were relatively young, and obesity has been most
strongly and consistently related to breast cancer in post-
menopausal women. Although national rates of breast cancer
have been correlated with consumption of animal fats and
other meat products, a high fat diet has been only weakly
and inconsistently related to breast cancer in case-control
studies, perhaps because the variation in fat intake within
countries is relatively small in comparison with international
variations in fat consumption (Prentice et al., 1990). Control-
ling for centre in this study effectively controlled for differ-
ences in fat intake among centres. Control for various indices
of socio-economic status would have partly controlled for
differences in fat intake between cases and controls within
centres. It is thus unlikely that the variation in fat intake
among individuals within centres, and the strength of the
association between fat intake and breast cancer, would be of
sufficient magnitude that residual confounding by fat intake
could explain the increased relative risk in users of oral
contraceptives.
Chance variation is also unlikely to be the sole explanation
for our findings. The 95% confidence intervals of the relative
risks in women who ever used oral contraceptives do not
include unity, when based either on data from all subjects in
the study, or on data from residents of the developing count-
ries; the relative risks were greater than 1 in 10 of the 12
centres, including eight of the nine in developing populations.
Although a combination of chance, and minor sources of
bias and confounding, could account for our results, a causal
interpretation must also be considered. Although risk was
observed to be highest in the longest use category (Table IV),
an increase with duration of exposure was not observed after
stratifying on months since most recent exposure (Table VI).
This absence of a trend of increasing risk with duration of
use, and lack of an increase in risk with time since first use,
are not observations that one would expect if oral contra-
ceptives were involved in initiating a carcinogenic process. In
this study, an enhanced risk was observed in current and
recent users, and there was a decline in risk with time since
last use. Similar observations have been reported at least to
some extent from four previous investigations (Fasel et al.,
1975; Brinton et al., 1982; Harris et al., 1982; Meirik et al.,
1986), but not from two others (Vessey et al., 1983; Cancer
and Steroid Hormone Study, 1986). Such a relationship
would be compatible with a late stage carcinogenic effect of
oral contraceptives on the breast. If such an effect exists, it is
not potentiated by other known risk factors for breast
cancer, because the relative risk in relation to oral contra-
ceptives was not greater in individuals with than without
such risk factors as older age, older age at first birth, nulli-
parity, high socio-economic status, family history of breast
cancer (Table VII) or history of benign breast disease. Prior
studies have also not consistently demonstrated interactions
between oral contraceptives and age at first birth, parity,
family history of breast cancer or prior benign breast disease
(Thomas, 1988). There is thus little or no reason to advise
women to avoid using oral contraceptives if they have one or
more of these features that are associated with an increased
risk.
The difference in the relative risks of 1.07 and 1.24
observed in developed and developing countries, respectively,
could be due to chance or to unrecognised sources of bias or
confounding that were operative primarily in the less devel-
oped countries in which this study was conducted. Alterna-
tively, these findings are compatible with oral contraceptives
exerting a small additive effect on risk of equal magnitude in
countries with varying underlying rates of breast cancer.118 WHO COLLABORATIVE STUDY
Thus, even if the relative risks are truly higher in the devel-
oping countries, the numbers of cases per 100,000 women
years of exposure attributable to use of oral contraceptives
would not be greater than in the developed countries because
of their lower underlying incidence rates.
If oral contraceptives were to enhance risk of breast cancer
by only a small absolute number of additional cases per
100,000 women years of use, then it is not surprising that
prior studies conducted largely in high rate countries have
failed to detect such small increases in risk. Epidemiological
methods currently available may not be sufficiently sensitive
to do so. Conducting studies in low risk populations is one
way to enhance the likelihood of detecting a true, but small,
absolute increase in risk, because the relative risk in such
populations would be larger than in higher risk populations.
The results of this study serve to demonstrate the utility of
this approach. They also indicate that further studies of
breast cancer and oral contraceptives in low risk populations
are warranted to determine whether the findings presented in
this report can be replicated.
The possibility that use of oral contraceptives at an early
age, or before the birth of a woman's first child, enchances
risk of breast cancer has been the subject of considerable
study and debate in recent years. Prior investigations have
yielded inconsistent results. An increased risk in women who
used oral contraceptives before age 25 was found in three
studies (Pike et al., 1983; Olsson et al., 1985; Meirik et al.,
1986), but not in four others (Paul et al., 1986; Cancer and
Steroid Hormone Study, 1986; Miller et al., 1986, 1989). The
observed increase in risk in this study, of borderline statis-
tical significance, in women who had used oral contraceptives
before age 25 for over 2 years is somewhat supportive of the
notion that such use can enhance the development of breast
cancer; but the absence of a significant trend of increasing
risk with duration of use is not. By considering the size of the
tumours of diagnosis, evidence was provided that the
observed enhanced risk in long-term users before age 25 is
probably not due solely to preferential screening for breast
cancer in such women.
Significantly elevated relative risks in women who used
oral contraceptives before the birth of their first child have
been reported from four independent investigations
(Paffenbarger et al., 1980; Pike et al., 1981; Harris et al.,
1982; McPherson et al., 1987), but not from eight others
(Vessey et al., 1982; Hennekens et al., 1984; Stadel et al.,
1985; Lipnick et al., 1986; Meirik et al., 1986; Paul et al.,
1986; Miller et al., 1986; Jick et al., 1989). A small increase in
risk in women who used oral contraceptives for more than 2
years before their first live birth was observed in this study,
but this increase was found only in women whose live birth
was preceded by a pregnancy with a non-viable outcome, and
evidence has been presented that suggests that this observa-
tion may be due to preferential screening of such users for
breast cancer. No satisfactory explanation has yet been found
for the inconsistent results among previous studies regarding
use before a woman's first birth. The findings from this study
offer a possible explanation, and it would be useful if others
would attempt to replicate them. Results from two recent
case-control studies (Miller et al., 1989; UK National
Case-Control Study Group, 1989) showed increased relative
risks of breast cancer in young women in relation to use of
oral contraceptives, irrespective of whether the use was
before or after the birth of the woman's first child. The
findings from this study are broadly consistent with these
results.
The data collection centres, and the principal investigator (PI), co-
investigator (CI) and pathologist (P) at each participating centre in
alphabetical order by country, are as follows:
University of Sydney, Department of Public Health, Sydney, Aust-
ralia: Geoffrey Berry (PI), Robert MacLennan (CI), Rodney
Shearman (CI), Tatiana Jelihovsky (P), Joan Cooper Booth (P).
University of Chile, Faculty of Medicine, Hospital Jose Joaquin
Aguirre, Department of Obstetrics and Gynaecology, and the
Ministry of Health, Hospital Salvador, Department of Obstetrics
and Gynaecology, Santiago, Chile: Ramiro Molina (PI), Luis Mar-
tinez (CI), Oriana Salas (CI), Alfredo Dabancens (P).
Shanghai Institute ofPlanned Parenthood Research, Shanghai, China:
Chen Zhiheng (PI), Tao Yun (CI), Hu Yong Wei (P).
Hospital Universitario, WHO Collaborative Centre for Research in
Human Reproduction, Cali, Colombia: Alvaro Cuadros (PI),
Nubia Aristizabal (P).
Central Institute of Cancer Research, Academy of Sciences of the
German Democratic Republic, Berlin, GDR: K. Ebeling (PI), P.
Nishan (CI), D. Kunde (P).
Chiam Sheba Medical Centre, Department of Clinical Epidemiology,
Tel Hashomer, Israel: Baruch Modan (PI), Elaine Ron (CI), Ester
Alfandary (CI).
University ofNairobi, Nairobi Centre for Research in Reproduction,
Nairobi, Kenya: J.G. Mati (PI), Patrick Kenya (CI), Alfred
Kungu (P), D. Gatei (P).
Hospital General de Mexico, Mexico City: Hector Rodriguez Cuevas
(PI), Socorro Benavides Salazar (CI), Antonio Palet (P), Patricia
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